Loading company…
Starna Therapeutics develops RNA medicines and delivery systems based on mRNA and lipid nanoparticle technologies.
Starna Therapeutics develops RNA therapeutics and delivery solutions using mRNA platforms and lipid nanoparticles, with work spanning molecule discovery, formulation and preclinical research. Its pipeline includes mRNA vaccines and therapies, and the company is advancing in vivo CAR-T candidates and delivery platforms for the lungs, intestines and nervous system. Founded in 2021, it is based in Suzhou, China. In May 2026, it raised approximately USD 40 million in Series B+ funding from GL Ventures, LYFE Capital, Lilly Asia Ventures, Sherpa Healthcare Partners, Source Code Capital and Primavera Capital Group.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in